Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115.
Department of Surgery, Harvard Medical School and Boston Children's Hospital, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2204758119. doi: 10.1073/pnas.2204758119. Epub 2022 Oct 3.
Obesity is associated with an increased risk of, and a poor prognosis for, postmenopausal (PM) breast cancer (BC). Our goal was to determine whether diet-induced obesity (DIO) promotes 1) shorter tumor latency, 2) an escape from tumor dormancy, and 3) an acceleration of tumor growth and to elucidate the underlying mechanism(s). We have developed in vitro assays and PM breast tumor models complemented by a noninvasive imaging system to detect vascular invasion of dormant tumors and have used them to determine whether obesity promotes the escape from breast tumor dormancy and tumor growth by facilitating the switch to the vascular phenotype (SVP) in PM BC. Obese mice had significantly higher tumor frequency, higher tumor volume, and lower overall survival compared with lean mice. We demonstrate that DIO exacerbates mammary gland hyperplasia and neoplasia, reduces tumor latency, and increases tumor frequency via an earlier acquisition of the SVP. DIO establishes a local and systemic proangiogenic and inflammatory environment via the up-regulation of lipocalin-2 (LCN2), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) that may promote the escape from tumor dormancy and tumor progression. In addition, we show that targeting neovascularization via a multitargeted receptor tyrosine kinase inhibitor, sunitinib, can delay the acquisition of the SVP, thereby prolonging tumor latency, reducing tumor frequency, and increasing tumor-free survival, suggesting that targeting neovascularization may be a potential therapeutic strategy in obesity-associated PM BC progression. This study establishes the link between obesity and PM BC and, for the first time to our knowledge, bridges the dysfunctional neovascularization of obesity with the earliest stages of tumor development.
肥胖与绝经后(PM)乳腺癌(BC)的风险增加和预后不良相关。我们的目标是确定饮食诱导的肥胖(DIO)是否促进 1)肿瘤潜伏期缩短,2)肿瘤休眠逃逸,3)肿瘤生长加速,并阐明潜在的机制。我们开发了体外检测和 PM 乳腺癌肿瘤模型,同时结合一种非侵入性成像系统来检测休眠肿瘤的血管浸润,并使用它们来确定肥胖是否通过促进 PM BC 向血管表型(SVP)的转变来促进肿瘤休眠逃逸和肿瘤生长。肥胖小鼠的肿瘤发生率、肿瘤体积和总生存率明显高于瘦小鼠。我们证明 DIO 通过更早地获得 SVP 来加重乳腺增生和肿瘤发生,缩短肿瘤潜伏期并增加肿瘤发生率。DIO 通过上调脂联素 2(LCN2)、血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF),建立局部和全身促血管生成和炎症环境,这可能促进肿瘤休眠逃逸和肿瘤进展。此外,我们还表明,通过多靶点受体酪氨酸激酶抑制剂舒尼替尼靶向新生血管化可以延迟 SVP 的获得,从而延长肿瘤潜伏期、降低肿瘤发生率并增加无肿瘤存活时间,这表明靶向新生血管化可能是肥胖相关 PM BC 进展的潜在治疗策略。这项研究建立了肥胖与 PM BC 之间的联系,并且据我们所知,首次将肥胖的功能失调性新生血管化与肿瘤发展的最早阶段联系起来。